UCB Reports the Results for Nayzilam in P-III Trial for the Treatment of Epilepsy
Shots:
- The P-III OLE study evaluates the safety of repeated intermittent use of Nayzilam (5mg) in patients (n=161, receiving 1 or 2 doses) with epilepsy experiencing seizure clusters (1,996 in 161 patients ) for a duration of 17mos. The results from the study were published in the ‘Epilepsy & Behavior’
- The results depicted a similar median time to RTFBF in both cohorts with ~30% of patients returning to baseline at 30mins & 50% within 1hr. Moreover, when observed at 1hr & 24hrs interval, 45.9% & 97.2% of patients receiving 1 dose & 44.7% & 94.2% of those receiving 2 dose returned to baseline
- Nayzilam (midazolam) was approved by the US FDA in 2019 as a nasal treatment of seizure clusters in epileptic patients aged ≥12yrs.
Ref: PR Newswire | Image: UCB
Related News:- UCB's Nayzilam (midazolam) Receives FDA's Approval for the Treatment of Seizure Cluster in Epilepsy in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
